TELLOMAK: T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY: AN OPEN LABEL, MULTI-COHORT, MULTI-CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T-CELL LYMPHOMA

Authors :: Hélène Sicard
Pierluigi Porcu
P. L. Zinzani
Youn H. Kim
H. A Azim
Martine Bagot
Source :: Hematological Oncology. 37:72-73
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
business.industry
medicine.medical_treatment
Phases of clinical research
Hematology
General Medicine
medicine.disease
KIR3DL2
Internal medicine
Cohort
medicine
T-cell lymphoma
Center (algebra and category theory)
In patient
Open label
business

Tools